Contact information

Patient name:

Unique patient identifier:

Patient parent/guardian contact information:

Controlled Access Programme ID (CAP ID):

Hospital where treated with crovalimab:

Treating doctor (prescriber)

Name:

Contact number:

▼ *This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See final page for details on how to report.*

Roche

PiaSky®▼(crovalimab) Patient Card

Important Safety Information for patients prescribed crovalimab or for whom the prescribing decision has been made

Show this card to any Healthcare Professional involved in your care.

M-GB-00018543
Version 1.0 . August 2024
MHRA Approval Date: 5th September 2024

Information for the patient

You have been prescribed crovalimab as treatment for paroxysmal nocturnal haemoglobinuria (PNH). For more information on crovalimab, refer to the crovalimab Patient Information Leaflet, accessible at www.medicines.org.uk/emc if based in Great Britain or www.emcmedicines.com/en-gb/northernireland if based in Northern Ireland.

Crovalimab may make you less able to fight infections, especially meningococcal infections, which require immediate emergency medical attention.

Immediately seek emergency medical attention if you have the following symptoms of possible meningococcal infection:

- Fever
- Feeling sick (nausea or vomiting)
- Headaches
- Confusion or irritability
- Stiff neck or back
- Muscle aches with flu-like symptoms
- Sensitivity of the eyes to light
- Skin rashes or spots

Meningococcal infections may become rapidly life-threatening or fatal if not recognised and treated early.

Crovalimab may cause severe allergic reactions

Immediately seek emergency medical attention if you have the following symptoms of possible severe allergic reaction soon after crovalimab administration:

- Tight chest or wheezing
- Feeling short of breath
- Fever or chills
- Severe dizziness, or light headedness
- Swelling of the lips, tongue, face
- Skin itching, hives, or rash

- Always carry this card with you while you are on crovalimab treatment and for 11 months after your last crovalimab dose. Your risk of meningococcal infection may continue for several months after your last dose of crovalimab
- Show this card to any doctor, nurse or pharmacist involved in your care
- Your pharmacist must include your CAP ID on the order when ordering crovalimab

Reporting of side effects:

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report side effects to the MHRA through the Yellow Card scheme, via the Yellow Card website www.mhra.gov.uk/yellowcard, the free Yellow Card app available in Apple App Store or Google Play Store. Alternatively you can call 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

By reporting suspected side effects, you can help provide more information on the safety of this medicine.

You should also report side effects to Roche Products Ltd by emailing the Roche Drug Safety Centre at welwyn.uk_dsc@roche.com or calling +44 (0) 1707 367554.

This educational material is provided by Roche Products Limited and mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks.

Information for the treating doctor

This patient has been prescribed crovalimab, a complement C5 inhibitor, which may make them more susceptible to meningococcal infection.

- Meningococcal infections may become rapidly life-threatening or fatal if not recognized and treated early
- Evaluate immediately if infection is suspected and treat as appropriate
- **Contact the prescribing doctor (listed on this card)** as soon as possible

Please consult the Summary of Product Characteristics for Piasky (crovalimab) available at: www.medicines.org.uk/emc if based in Great Britain or www.emcmedicines.com/en-gb/northernireland if based in Northern Ireland; or contact Roche Medical Information (tel: 0800 328 1629, email: medinfo.uk@roche.com).